Palobiofarma SL
🇪🇸Spain
- Country
- 🇪🇸Spain
- Ownership
- Holding
- Established
- 2005-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.palobiofarma.com
Therapeutic Effect of PBF-680 in Patients With COPD
Phase 2
Completed
- Conditions
- COPD
- Interventions
- Drug: PlaceboDrug: PBF-680 10mg
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Palobiofarma SL
- Target Recruit Count
- 174
- Registration Number
- NCT05262218
- Locations
- 🇪🇸
Hospital Bellvitge, Barcelona, Spain
🇪🇸Hospital Clinic, Barcelona, Spain
🇪🇸Hospital del Mar, Barcelona, Spain
Study to Assess the Safety and Tolerability of PBF-1650 in Healthy Volunteers.
Phase 1
Completed
- Conditions
- Psoriasis
- Interventions
- Drug: PBF-1650 oral capsulesDrug: Placebo oral capsule
- First Posted Date
- 2019-01-09
- Last Posted Date
- 2020-06-30
- Lead Sponsor
- Palobiofarma SL
- Target Recruit Count
- 32
- Registration Number
- NCT03798236
- Locations
- 🇪🇸
Clinica Universidad de Navarra, Pamplona, Navarra, Spain
Study of PBF-999 in Solid Tumour Advanced Cancer
- First Posted Date
- 2018-12-26
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Palobiofarma SL
- Target Recruit Count
- 54
- Registration Number
- NCT03786484
- Locations
- 🇪🇸
Vall d'Hebron institute of oncology (VHIO), Barcelona, Spain
Safety and Efficacy of PBF-677 in Ulcerative Colitis Patients
- First Posted Date
- 2018-12-12
- Last Posted Date
- 2022-01-13
- Lead Sponsor
- Palobiofarma SL
- Target Recruit Count
- 34
- Registration Number
- NCT03773952
- Locations
- 🇪🇸
Unidad de Enfermedad Inflamatoria Intestinal / IBD Unit. Servicio de Gastroenterología y Hepatología / Gastroenterology and Hepatology Dpt. Study Medical Coordinator Hospital Universitario Puerta de Hierro, Madrid, Spain
Study to Investigate the Effect of PBF-680 on Forced Expiratory Volume in 1 Second (FEV1) in Asthmatic Patients
- First Posted Date
- 2018-12-12
- Last Posted Date
- 2020-09-25
- Lead Sponsor
- Palobiofarma SL
- Target Recruit Count
- 107
- Registration Number
- NCT03774290
- Locations
- 🇪🇸
Unitat de Pneumologia Experimental, Barcelona, Spain
PBF-1129 in Patients With NSCLC
Phase 1
Active, not recruiting
- Conditions
- Locally Advanced or Metastatic NSCLC
- Interventions
- First Posted Date
- 2017-09-07
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Palobiofarma SL
- Target Recruit Count
- 18
- Registration Number
- NCT03274479
- Locations
- 🇺🇸
Division of medical Oncology A450B Starling Loving Hall, Ohio City, Ohio, United States
Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 "After Multiple Oral Doses" in Healthy Volunteers
Phase 1
Terminated
- Conditions
- Huntington Disease
- Interventions
- Drug: PlaceboDrug: PBF-999 / 160 mgDrug: PBF-999 / 320 mg
- First Posted Date
- 2016-09-20
- Last Posted Date
- 2016-09-20
- Lead Sponsor
- Palobiofarma SL
- Target Recruit Count
- 8
- Registration Number
- NCT02907294
- Locations
- 🇪🇸
CIM-Sant Pau, Barcelona, Spain
"First-in-human" Study To Assess the Safety and Tolerability of PBF-677 in Healthy Volunteers
- First Posted Date
- 2015-12-28
- Last Posted Date
- 2018-12-17
- Lead Sponsor
- Palobiofarma SL
- Target Recruit Count
- 32
- Registration Number
- NCT02639975
A Study to Assess the Efficacy of a 5-day, 10- mg PBF-680 Oral Administration on Late Asthmatic Responses (LAR) in Mild to Moderate Asthmatic Patients.
- First Posted Date
- 2015-12-21
- Last Posted Date
- 2020-06-30
- Lead Sponsor
- Palobiofarma SL
- Target Recruit Count
- 8
- Registration Number
- NCT02635945
- Locations
- 🇪🇸
Unitat de Pneumologia Experimental, Barcelona, Spain
Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Phase 1
Completed
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Drug: PBF-509_160 mgDrug: PBF-509_80 mgDrug: PBF-509_640 mgDrug: PBF-509_320 mgDrug: RP2D (PBF-509+PDR001)_immuno naïveDrug: Combo PBF-509 (160 mg) + PDR001Drug: Combo PBF-509 (320 mg) + PDR001Drug: Combo PBF-509 (640 mg) + PDR001
- First Posted Date
- 2015-03-31
- Last Posted Date
- 2022-01-12
- Lead Sponsor
- Palobiofarma SL
- Target Recruit Count
- 92
- Registration Number
- NCT02403193
- Locations
- 🇺🇸
H.Lee Moffitt Cancer center, Tampa, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath